MetaCap

Eikon Therapeutics (EIKN) vs Ocugen (OCGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ocugen is the larger company by market cap ($260.6 million vs $256.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EIKN-68.40%OCGN-42.26%
+94%+9%-76%
Feb 5, 20261 yearNov 20, 2026
EIKN-67.31%OCGN-42.26%
+94%+10%-75%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EIKN versus OCGN key metrics
MetricEIKNOCGN
Share price$4.74$0.7679
Market cap$256.84M$260.55M
1-day change-0.42%+4.79%
YTD return—-43.12%
1-year return—-33.80%
5-year return—-88.09%
EPS (TTM)$-7.86$-0.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$4.41M
Revenue growth (YoY)—+8.83%
Net income (latest FY)—$-67.85M
Operating margin—-1425.70%
Net margin—-1537.41%
52-week high$17.40$2.73
52-week low$4.72$0.691
Distance from 52-week high-72.76%-71.82%
Analyst consensusbuystrong_buy
Avg. price target upside+406.33%+1484.84%
Average volume560.40K7.34M
Shares outstanding54.19M339.31M
Employees384116
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Eikon Therapeutics

EIKN stock →

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 384 employees

About Ocugen

OCGN stock →

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 116 employees

EIKN vs OCGN FAQ

Which is bigger, Eikon Therapeutics or Ocugen?

Ocugen (OCGN) is larger, with a market capitalization of $260.55M compared with $256.84M for Eikon Therapeutics (EIKN).

Are Eikon Therapeutics and Ocugen in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons